Based on the information, we designed and synthesized compound 1 (Npx-DFDFGSSSR, Figure 1A) containing DFDF and the tetrapeptide SSSR from IGF-1 with the anti-inflammatory drug naproxen (Npx) as a capping group to explore its therapeutic effect on atherosclerosis. This evidence concerns the gene IGF1 and atherosclerosis.